BACKGROUND: Long-term medication therapy for patients with post-myocardial infarction (MI) can prolong life. However, recent data on long-term adherence are limited, particularly among some subpopulations. We compared medication adherence among Medicare MI survivors by disability status, race/ethnicity, and income. METHODS: We examined 100% of Medicare fee-for-service beneficiaries discharged post-MI in 2008. The outcomes were adherence to β-blockers, statins, and angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers, for 1-year and 6-month postdischarge. Adherence was defined as having prescriptions in possession for ≥75% of days. RESULTS: Among aged beneficiaries who survived 1-year adherence to β-blockers were 68%, 66%, 61%, 58%, and 57% for whites, Asians, Hispanics, Native Americans, and blacks, respectively; among persons with disability, 1-year adherence was worse for each group: 59%, 54%, 52%, 47%, and 43%, respectively. The racial/ethnic difference persisted after adjustment for age, gender, income, drug coverage, location, and health status. Patterns of adherence to statins and angiotensin-converting enzymes/angiotensin II receptor blockers were similar. Among beneficiaries with close-to-full drug coverage, minorities were still less likely to adhere relative to whites: odds ratio 0.70 (95% CI 0.65-0.75) for blacks and odds ratio 0.70 (95% CI 0.55-0.90) for Native Americans. CONCLUSIONS: Although β-blockers at discharge has improved since the National Committee for Quality Assurance implemented quality measures, long-term adherence remains problematic, especially among persons with disability and minority beneficiaries. Quality measures for long-term adherence should be created to improve outcomes in patients with post-MI. Even among those with close-to-full drug coverage, racial differences remain, suggesting that policies simply relying on cost reduction cannot eliminate racial differences.
BACKGROUND: Long-term medication therapy for patients with post-myocardial infarction (MI) can prolong life. However, recent data on long-term adherence are limited, particularly among some subpopulations. We compared medication adherence among Medicare MI survivors by disability status, race/ethnicity, and income. METHODS: We examined 100% of Medicare fee-for-service beneficiaries discharged post-MI in 2008. The outcomes were adherence to β-blockers, statins, and angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers, for 1-year and 6-month postdischarge. Adherence was defined as having prescriptions in possession for ≥75% of days. RESULTS: Among aged beneficiaries who survived 1-year adherence to β-blockers were 68%, 66%, 61%, 58%, and 57% for whites, Asians, Hispanics, Native Americans, and blacks, respectively; among persons with disability, 1-year adherence was worse for each group: 59%, 54%, 52%, 47%, and 43%, respectively. The racial/ethnic difference persisted after adjustment for age, gender, income, drug coverage, location, and health status. Patterns of adherence to statins and angiotensin-converting enzymes/angiotensin II receptor blockers were similar. Among beneficiaries with close-to-full drug coverage, minorities were still less likely to adhere relative to whites: odds ratio 0.70 (95% CI 0.65-0.75) for blacks and odds ratio 0.70 (95% CI 0.55-0.90) for Native Americans. CONCLUSIONS: Although β-blockers at discharge has improved since the National Committee for Quality Assurance implemented quality measures, long-term adherence remains problematic, especially among persons with disability and minority beneficiaries. Quality measures for long-term adherence should be created to improve outcomes in patients with post-MI. Even among those with close-to-full drug coverage, racial differences remain, suggesting that policies simply relying on cost reduction cannot eliminate racial differences.
Authors: K A Phillips; M G Shlipak; P Coxson; P A Heidenreich; M G Hunink; P A Goldman; L W Williams; M C Weinstein; L Goldman Journal: JAMA Date: 2000-12-06 Impact factor: 56.272
Authors: Véronique L Roger; Alan S Go; Donald M Lloyd-Jones; Robert J Adams; Jarett D Berry; Todd M Brown; Mercedes R Carnethon; Shifan Dai; Giovanni de Simone; Earl S Ford; Caroline S Fox; Heather J Fullerton; Cathleen Gillespie; Kurt J Greenlund; Susan M Hailpern; John A Heit; P Michael Ho; Virginia J Howard; Brett M Kissela; Steven J Kittner; Daniel T Lackland; Judith H Lichtman; Lynda D Lisabeth; Diane M Makuc; Gregory M Marcus; Ariane Marelli; David B Matchar; Mary M McDermott; James B Meigs; Claudia S Moy; Dariush Mozaffarian; Michael E Mussolino; Graham Nichol; Nina P Paynter; Wayne D Rosamond; Paul D Sorlie; Randall S Stafford; Tanya N Turan; Melanie B Turner; Nathan D Wong; Judith Wylie-Rosett Journal: Circulation Date: 2010-12-15 Impact factor: 29.690
Authors: Elliott M Antman; Mary Hand; Paul W Armstrong; Eric R Bates; Lee A Green; Lakshmi K Halasyamani; Judith S Hochman; Harlan M Krumholz; Gervasio A Lamas; Charles J Mullany; David L Pearle; Michael A Sloan; Sidney C Smith; Daniel T Anbe; Frederick G Kushner; Joseph P Ornato; Alice K Jacobs; Cynthia D Adams; Jeffrey L Anderson; Christopher E Buller; Mark A Creager; Steven M Ettinger; Jonathan L Halperin; Sharon A Hunt; Bruce W Lytle; Rick Nishimura; Richard L Page; Barbara Riegel; Lynn G Tarkington; Clyde W Yancy Journal: Circulation Date: 2007-12-10 Impact factor: 29.690
Authors: Niteesh K Choudhry; Jerry Avorn; Robert J Glynn; Elliott M Antman; Sebastian Schneeweiss; Michele Toscano; Lonny Reisman; Joaquim Fernandes; Claire Spettell; Joy L Lee; Raisa Levin; Troyen Brennan; William H Shrank Journal: N Engl J Med Date: 2011-11-14 Impact factor: 91.245
Authors: Judith M Kramer; Bradley Hammill; Kevin J Anstrom; Donald Fetterolf; Richard Snyder; John P Charde; Barbara S Hoffman; Nancy Allen LaPointe; Eric Peterson Journal: Am Heart J Date: 2006-09 Impact factor: 4.749
Authors: Niteesh K Choudhry; Soko Setoguchi; Raisa Levin; Wolfgang C Winkelmayer; William H Shrank Journal: Pharmacoepidemiol Drug Saf Date: 2008-12 Impact factor: 2.890
Authors: Ian M Kronish; Michael A Diefenbach; Donald E Edmondson; L Alison Phillips; Kezhen Fei; Carol R Horowitz Journal: J Gen Intern Med Date: 2013-01-04 Impact factor: 5.128
Authors: Michael G Nanna; Ann Marie Navar; Pearl Zakroysky; Qun Xiang; Anne C Goldberg; Jennifer Robinson; Veronique L Roger; Salim S Virani; Peter W F Wilson; Joseph Elassal; L Veronica Lee; Tracy Y Wang; Eric D Peterson Journal: JAMA Cardiol Date: 2018-08-01 Impact factor: 14.676
Authors: Leah L Zullig; Ryan J Shaw; Bimal R Shah; Eric D Peterson; Jennifer H Lindquist; Matthew J Crowley; Steven C Grambow; Hayden B Bosworth Journal: Patient Prefer Adherence Date: 2015-02-19 Impact factor: 2.711
Authors: Keith C Ferdinand; Kapil Yadav; Samar A Nasser; Helene D Clayton-Jeter; John Lewin; Dennis R Cryer; Fortunato Fred Senatore Journal: J Clin Hypertens (Greenwich) Date: 2017-08-30 Impact factor: 3.738